analogues were designed, synthesized, and evaluated as potential drugs for the treatment of Alzheimer's disease. By using a multitarget‐directed ligand approach, compounds were designed to act simultaneously as cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors. The compounds were also evaluated for antioxidant, cytotoxic, hepatotoxic, and blood–brain barrier (BBB) permeability properties. Indolotacrine
设计,合成和评估了新的
吲哚洛林类似物,作为治疗阿尔茨海默氏病的潜在药物。通过使用多靶标定向
配体方法,化合物被设计为同时充当
胆碱酯酶(ChE)和单胺氧化酶(MAO)
抑制剂。还评估了这些化合物的
抗氧化剂,细胞毒性,肝毒性和血脑屏障(BBB)渗透性。
吲哚洛林9 b(9-甲氧基-2,3,4,6-四氢-1 H-
吲哚[2,3 - b ]
喹啉-11-胺)在体外评估中显示出最有希望的结果; 它是
乙酰胆碱酯酶的强效
抑制剂(AChE的IC 50:1.5μ米),丁酰
胆碱酯酶(IC的BChE 50:2.4μ米)和MAO A(IC 50:0.49μ米),它也是MAO B的弱
抑制剂(IC 50:53.9μ米)。虽然它的细胞毒性(IC 50:5.5±0.4μ米)和肝毒性(IC 50:1.22±0.11μ米)配置文件是不如那些标准7- methoxytacrine的(IC 50:63±4和11.50±0.77μ m分别)